Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population

View ORCID ProfileJia Wei, Koen B. Pouwels, View ORCID ProfileNicole Stoesser, View ORCID ProfilePhilippa C. Matthews, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John I Bell, John N Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre, the COVID-19 Infection Survey team
doi: https://doi.org/10.1101/2021.09.13.21263487
Jia Wei
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jia Wei
Koen B. Pouwels
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
4Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Stoesser
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
5The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
6Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicole Stoesser
Philippa C. Matthews
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
6Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philippa C. Matthews
Ian Diamond
7Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Studley
7Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Rourke
7Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan Cook
7Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John I Bell
8Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John N Newton
9Health Improvement Directorate, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Farrar
10Wellcome Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison Howarth
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
6Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian D. Marsden
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
11Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Hoosdally
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Yvonne Jones
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David I Stuart
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derrick W. Crook
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
5The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
6Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim E. A. Peto
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
5The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
6Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Sarah Walker
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
12MRC Clinical Trials Unit at UCL, UCL, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Eyre
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
3The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
5The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
6Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.eyre{at}bdi.ox.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

We investigated anti-spike IgG antibody responses and correlates of protection following second doses of ChAdOx1 or BNT162b2 SARS-CoV-2 vaccines in the UK general population. In 222,493 individuals, we found significant boosting of anti-spike IgG by second doses of both vaccines in all ages and using different dosing intervals, including the 3-week interval for BNT162b2. After second vaccination, BNT162b2 generated higher peak levels than ChAdOX1. Antibody levels declined faster at older ages and in males with BNT162b2, but declines were similar across ages and sexes with ChAdOX1. Prior infection significantly increased antibody half-life with both vaccines. Anti-spike IgG levels were associated with protection from infection after vaccination and, to an even greater degree, after prior infection. At least 67% protection against infection was estimated to last for 2-3 months after two ChAdOx1 doses and 6-15 months after two BNT162b2 doses in those without prior infection, and 1-2 years for those unvaccinated after natural infection. A third booster dose may be needed, prioritised to ChAdOx1 recipients and those more clinically vulnerable.

Competing Interest Statement

DWE declares lecture fees from Gilead, outside the submitted work. No other author has a conflict of interest to declare.

Funding Statement

This study is funded by the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. ASW, TEAP, NS, DE, KBP are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (NIHR200915). ASW and TEAP are also supported by the NIHR Oxford Biomedical Research Centre. KBP is also supported by the Huo Family Foundation. ASW is also supported by core support from the Medical Research Council UK to the MRC Clinical Trials Unit [MC_UU_12023/22] and is an NIHR Senior Investigator. PCM is funded by Wellcome (intermediate fellowship, grant ref 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship award. DWE is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. NS is an Oxford Martin Fellow and holds an NIHR Oxford BRC Senior Fellowship.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • See Acknowledgements for the Coronavirus Infection Survey team

Data Availability

Data are still being collected for the COVID-19 Infection Survey. De-identified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. For further information about accreditation, contact Research.Support{at}ons.gov.uk or visit the SRS website.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 15, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population
Jia Wei, Koen B. Pouwels, Nicole Stoesser, Philippa C. Matthews, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John I Bell, John N Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre, the COVID-19 Infection Survey team
medRxiv 2021.09.13.21263487; doi: https://doi.org/10.1101/2021.09.13.21263487
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population
Jia Wei, Koen B. Pouwels, Nicole Stoesser, Philippa C. Matthews, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John I Bell, John N Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre, the COVID-19 Infection Survey team
medRxiv 2021.09.13.21263487; doi: https://doi.org/10.1101/2021.09.13.21263487

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (754)
  • Anesthesia (221)
  • Cardiovascular Medicine (3286)
  • Dentistry and Oral Medicine (363)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13352)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5142)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3263)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1016)
  • Infectious Diseases (except HIV/AIDS) (14618)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4916)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2518)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4201)
  • Public and Global Health (7492)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (204)